PharmaSGP Holding SE (DE:PSG)
XETRA:PSG
Germany Market
Holding DE:PSG?
Track your performance easily

PharmaSGP Holding SE (PSG) Income Statement

3 Followers

PharmaSGP Holding SE Income Statement

Last quarter (Q3 2022), PharmaSGP Holding SE's total revenue was €21.95M, an increase of 11.24% from the same quarter last year. In Q3, PharmaSGP Holding SE's net income was €3.95M. See PharmaSGP Holding SE’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19
Total Revenue
€ 83.13M€ 65.34M€ 63.25M€ 62.57M
Cost of Revenue
€ 9.40M€ 6.49M€ 6.21M€ 5.87M
Gross Profit
€ 73.73M€ 58.86M€ 57.04M€ 56.71M
Operating Expense
€ 56.61M€ 43.36M€ 40.97M€ 32.22M
Operating Income
€ 17.12M€ 15.49M€ 16.07M€ 24.48M
Net Non Operating Interest Income Expense
€ -1.88M€ -713.00K€ -99.00K€ -156.00K
Other Income Expense
----
Pretax Income
€ 14.67M€ 14.21M€ 14.15M€ 22.26M
Tax Provision
€ 3.67M€ 3.52M€ 3.51M€ 5.56M
Earnings From Equity Interest Net Of Tax
----
Net Income Common Stockholders
€ 11.00M€ 10.69M€ 10.64M€ 16.71M
Basic EPS
€ 0.92€ 0.89€ 0.89€ 1.39
Diluted EPS
€ 0.92€ 0.89€ 0.89€ 1.39
Basic Average Shares
€ 47.81M€ 12.00M€ 12.00M€ 12.00M
Diluted Average Shares
€ 47.81M€ 12.00M€ 12.00M€ 12.00M
Dividend Per Share
€ 0.45---
Total Operating Income As Reported
----
Reported Normalized Basic E P S
----
Reported Normalized Diluted E P S
----
Rent Expense Supplemental
----
Total Expenses
€ 66.00M€ 49.85M€ 47.17M€ 38.09M
Net Income From Continuing And Discontinued Operation
€ 11.00M€ 10.69M€ 10.64M€ 16.71M
Normalized Income
€ 11.00M€ 11.12M€ 12.01M€ 18.25M
Interest Expense
€ 1.81M€ 643.00K€ 75.00K€ 75.00K
EBIT
€ 16.48M€ 14.85M€ 14.22M€ 22.34M
EBITDA
€ 25.73M€ 18.42M€ 14.71M€ 22.73M
Currency in EUR

PharmaSGP Holding SE Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis